GlobeNewswire - Industry News on Biotechnology

Rezolute to Participate in Upcoming Investor Conferences in March

2021-03-02T22:16:56Z

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company��s CEO and Founder, will be presenting at the following upcoming investor conferences:

Pacific Biosciences Grants Equity Incentive Award to New Employee

2021-03-02T21:30:00Z

MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (��Pacific Biosciences�� or the ��Company��), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Company��s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock and restricted stock units (��RSUs��) covering 40,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the ��2020 Inducement Plan��) effective on February 25, 2021.

Chinook Therapeutics to Present at Upcoming Investor Conferences

2021-03-02T21:15:00Z

VANCOUVER, British Columbia and SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences:

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

2021-03-02T21:05:00Z

CAMBRIDGE, Mass. and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data from two programs emerging from the Company��s proprietary MAP platform targeting BRAF and fibroblast growth factor receptor (FGFR) at the European Society of Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021, taking place March 1-2, 2021.

REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021

2021-03-02T21:05:00Z

BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients

2021-03-02T21:02:12Z

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.?(Nasdaq: SRNE, ��Sorrento��) announced today that it has received clearance from the FDA for its Investigational New Drug application (IND) for its Phase 1 study of the safety and pharmacokinetics of intranasal (IN) STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.

Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021

2021-03-02T21:02:00Z

SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31, 2020, on Tuesday, March 23, 2021 after the close of the market.

Genocea to Present at the H.C. Wainwright Global Life Sciences Conference

2021-03-02T21:01:00Z

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Tuesday, March 9, 2021 at 7:00 A.M. ET.

NexImmune to Present at the 2021 Barclays Global Healthcare Conference

2021-03-02T21:01:00Z

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.?(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that?Scott Carmer, Chief Executive Officer, will present a company overview at the?virtual 2021 Barclays Global Healthcare Conference on?Thursday, March 11, 2021?at?10:55 a.m. Eastern time.

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

2021-03-02T20:31:47Z

Company Announcement

Capital Increase in Genmab as a Result of Employee Warrant Exercise

2021-03-02T20:26:50Z

Company Announcement

Global WholeHealth Partners Corp (GWHP-OTC) to Announce That the Antibody Test Kits Offered by Global Can Detect the S1 Protein Used in COVID 19 Vaccines

2021-03-02T19:31:59Z

People want to know if the vaccine worked; Global��s test will help people know if the IgG antibody is forming after the vaccine.

Transactions in connection with share buyback program

2021-03-02T17:59:32Z

Company announcement no. 10 - 21
2 March 2021

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

2021-03-02T14:48:19Z

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (��Cullinan��), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company��s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.

BioCorRx Completes $2.25 Million Private Placement

2021-03-02T14:24:48Z

ANAHEIM, CA, March 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire?--?BioCorRx Inc. (OTCQB: BICX) (the ��Company��),?a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that the Company completed a private placement, whereby it issued 1.125 million common stock shares at a price of $2.00 per share, for total proceeds of $2.25 million. The private placement was done with Louis Lucido and Joseph Galligan, both members of the Company��s Board of Directors.

CohBar to Present at the 33rd Annual ROTH Conference

2021-03-02T14:00:00Z

MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will participate in a fireside chat with ROTH Senior Research Analyst Elemer Piros, Ph.D. at the 33^rd Annual ROTH Conference, being held virtually March 15 �C 17, 2021.

Innovation Pharmaceuticals Announces Publication of Peer-Reviewed Scientific Article in the Journal Viruses on the Anti-SARS-CoV-2 Properties of Brilacidin

2021-03-02T14:00:00Z

WAKEFIELD, MA, March 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (��the Company��), a clinical stage biopharmaceutical company, today announced the publication of a peer-reviewed scientific article��Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture��in the journal Viruses.

Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies

2021-03-02T14:00:00Z

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has cleared Sorrento��s internally developed anti-CD47 monoclonal antibody, STI-6643, which was discovered from Sorrento's G-MAB? library, for an initial clinical trial. The initial clinical trial will be a basket trial entitled ��A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Patients with Selected Relapsed or Refractory Malignancies.��??

LIDDS enters R&D agreement with potential exclusive, global product license option

2021-03-02T13:50:00Z

UPPSALA, SWEDEN �C LIDDS AB (publ) announced today that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid? technology for an undisclosed indication.

PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization

2021-03-02T13:30:25Z

OXFORD, Ohio and COCONUT CREEK, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- PsyBio Therapeutics Corp. (TSXV:PSYB) (��PsyBio�� or the ��Company��), a leader in the field of psychedelic research and drug development, has initiated pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc. (��AMRI��), a leading global provider of advanced contract research, development and manufacturing solutions, with expertise in synthetic biology and fermentation development. The Company has completed Phase I of this process, including technology transfer activities, preparation of strain banks, and the adoption of analytical methods and looks forward to communicating additional progress.